Tenax Therapeutics (NASDAQ:TENX) Announces Earnings Results

Key Points

• Tenax reported a quarterly loss of $0.31 per share, narrower than analysts’ expected loss of $0.35.
• Shares fell 9.9% to $1.63 on Thursday. The stock has a consensus “Hold” rating, while several insiders and a major shareholder recently purchased shares.
• The company said LEVEL trial analysis could inform an amended LEVEL-2 protocol and that it received an FDA Type C meeting. Separately, investors have filed a securities class action alleging Tenax overstated TNX-103’s prospects; those allegations have not been proven.

Tenax Therapeutics (NASDAQ:TENX - Get Free Report) posted its earnings results on Thursday. The specialty pharmaceutical company reported ($0.31) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.04, FiscalAI reports.

Tenax Therapeutics Trading Down 9.9%

Shares of TENX stock traded down $0.18 during trading hours on Thursday, reaching $1.63. 1,959,451 shares of the company's stock were exchanged, compared to its average volume of 2,217,301. Tenax Therapeutics has a fifty-two week low of $1.31 and a fifty-two week high of $19.40. The stock's 50 day moving average is $1.83 and its 200-day moving average is $9.89. The company has a market cap of $60.99 million, a price-to-earnings ratio of -1.10 and a beta of 0.99.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Weiss Ratings lowered Tenax Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Monday, September 14th. UBS Group downgraded Tenax Therapeutics to a "neutral" rating in a research report on Monday, August 31st. Evercore lowered Tenax Therapeutics from an "outperform" rating to an "in-line" rating and set a $5.00 target price on the stock. in a research note on Tuesday, August 11th. Leerink Partners set a $4.00 target price on shares of Tenax Therapeutics in a report on Tuesday, August 11th. Finally, Canaccord Genuity Group set a $4.00 price target on shares of Tenax Therapeutics and gave the company a "buy" rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Tenax Therapeutics presently has an average rating of "Hold" and a consensus price target of $14.00.

Insiders Place Their Bets

In other Tenax Therapeutics news, Director Declan Doogan bought 53,000 shares of the company's stock in a transaction that occurred on Wednesday, September 16th. The shares were purchased at an average cost of $1.92 per share, for a total transaction of $101,760.00. Following the purchase, the director directly owned 55,274 shares in the company, valued at $106,126.08. This represents a 2,330.69% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Adar1 Capital Management, Llc bought 331,979 shares of the company's stock in a transaction that occurred on Wednesday, October 21st. The shares were acquired at an average price of $1.66 per share, for a total transaction of $551,085.14. Following the completion of the purchase, the insider owned 7,447,000 shares in the company, valued at $12,362,020. The trade was a 4.67% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 3,682,899 shares of company stock valued at $6,388,279 in the last three months. Insiders own 10.81% of the company's stock.

Tenax Therapeutics News Roundup

Here are the key news stories impacting Tenax Therapeutics this week:

• Positive Sentiment: Tenax reported a third-quarter loss of $0.31 per share, narrower than analysts’ expected loss of $0.35. Read More.
• Positive Sentiment: The company said its analysis of the LEVEL trial identified a potential patient-enrichment strategy that it is incorporating into an amended LEVEL-2 protocol. Tenax also received a Type C meeting with the FDA, providing an opportunity to discuss its development plans. These updates may support the program, though they do not erase the earlier trial setback. Read More.
• Negative Sentiment: Several law firms publicized a securities class action filed on behalf of investors who bought TENX shares between November 13, 2023 and August 7, 2026. The complaint alleges Tenax overstated TNX-103’s clinical prospects while raising capital before the Phase 3 LEVEL trial missed its primary endpoint. The allegations have not been proven; the lead-plaintiff deadline is December 28, 2026. The litigation risk and trial disappointment are potential headwinds for the stock. Read More.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and pulmonary diseases. The company's research programs are aimed at addressing conditions with significant unmet medical needs, including pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

Tenax's lead product candidate is TNX-103, an oral formulation of levosimendan. Levosimendan is a calcium sensitizer and potassium-channel activator that has been approved for certain heart-failure indications outside the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.